Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bosco & Crossy's stock picks,talk area -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (3428)	6/12/2003 11:32:51 AM
From: Crossy	Respond to of 37387

How I found them ? Think it was mentioned on one board as a generics play (on Yahoo) which prompted me to examine it more carefully early 2003. I followed the Able Labs story (Nasdaq: ABRX) pretty close and so I'm quite familiar with the possibilities in this sector. What atteracted me was certainly the generics side, not the old NEOT biotech research company.. I view SPPI as a company that will have a "balanced portfolio" soon: obtaining generics revenues to finance biotech research and more. Not the usual cash-loaded biotech operation with little or no revenues - which is typical for the industry but where I do not like to put my money into. SPPI could become another RGEN in this regard. They too have a balanced portfolio - biotech R&D and steady revenues from biomaterials - Protein A. In such situations (like RGEN and SPPI's future biz model) risk is greatly reduced. Not need for constant tapping the capital markets and the associated dilution.. That's what I like so much. rgrds CROSSY

To: Icebrg who wrote (3428)	6/12/2003 12:07:42 PM
From: Icebrg	Respond to of 37387

Re: Any CC news? TIA by: urche2002 (50/M/vermont) Long-Term Sentiment: Hold 06/12/03 11:44 am Msg: 31960 of 31962 [This is a summary of today's cc. I know urche mailwise. He is a MD although not an oncologist and should know what he is talking about. Erik] I listened. It was well done but I did not hear anything new that was significant enough to move the price up further today. Raj gave all of the prepared remarks. Dr. Lenaz answered a couple of questions. J. McManus was present but did not speak. Raj reviewed satraplatin data presented at ASCO and some relevant history of the drug. He stated the ph. III study in hormone refractory prostate cancer will be completed by 2006, with the possibility of earlier release following interim analyses. Some info regarding Eoquin was new to me. As revealed in data released this week, 5/5 patients with bladder cancer have responded to Eoquin with remission at 3-9 month surveillance. These patients all had had recurrence of tumor following surgery, BCG, or other standard treatment. I was hoping to verify that these patients received no concurrent treatment (such as repeat cystoscopic surgery) at the time Eoquin was administered. Unfortunately, my question was not recognized, so I am left assuming these patients responded to Eoquin and Eoquin alone. But, thus far the surveillance period is short, and I did not hear it stated explicitly that these patients were tumor free at 3-9 months on the basis of repeat cystoscopy and biopsy, which I believe would be the gold standard. So, I am tentatively enthused by these results. Now that a dose has been selected, the next step is a larger study involving 40-50 patients at centers in Belgium and Netherlands. Eoquin use as a radiation sensitizer was only mentionned in passing. Elsamutricin was also discussed briefly. I think we can expect data in first half of next year on its use in patients with refractory non-Hodgkins Lymphoma. Raj went out of his way to assert that he expects both the elsamutricin ph II and satraplatin ph III studies to be completed with no significant increase from the $500,000 per month budget. (That figure does not sound right but that is what I wrote down). Raj also announced his intention to in-license at least 1 additional oncology drug this year. There were three questions. One of them asked for details on the deal for satraplatin royalties beyond the disclosed $22 million in milestones. Raj would only reveal that additional royalties would be earned, assuming ph. III studies are successful. Overall, I'd say the conference call served to reinforce, reemphasize the flurry of recent news events from Spectrum. As such, it will likely be disappointing to those who follow the company closely, but probably was useful strategically to keep Spectrum in the public and institutional limelight. For those interested in hearing it themselves it will be available a few hours after the live call, I think both by phone or web--ask for code #1262108. urche